Mironid: Mironid Presents Translational Data in Oral Presentation at
Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress LoAc® compound lowers renal cAMP after single or multiple doses and demonstrates efficacy in a preclinical model of ADPKDMironid will select a development candidate from its LoAc® programme to advance as a treatment for ADPKD 28 May 2024, Glasgow, Scotland - Mironid, [...]
Read full article »
Mironid is a Scotland-based biopharmaceutical company that researches and develops small-molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease.
Read more